As for dilution he is doing what most CEO of biotech companies in US would do. Dilution is the normal way of financing a non revenue generating company.
What most worries me most , and the main reason why I am out of VBLT now, if we forget about fierce competition in the cancer arena and some other companies encouraging results also in rGBM, is that VBLT actual trial results do not reconcile with what the CEO keeps claiming about VBLT efficacy. GBM ph2 results did NOT show 15 months median OS and prOC did NOT show 812 median OS. This to me is false and misleading information issued by a publicly traded company, which in US is a crime. I tried to ask explanations from IR and Lifescience Capital and I never got any replies.
The issue is that Mr Dror is not a US citizen and not sure if he can even be prosecuted in Israel ... hence maybe he does not care too much... he just keeps repeating 812 days and 15 months even if he knows that in fact we are talking about 400 something days and 13.7 months respectively.
I have no position in VBLT and no interest in writing all this. I would just like that capital is allocated to the right companies which contribute to make a terrible disease more treatable and eventually curable.
News 
Market Data 
Discover 
